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ABSTRACT
Background Fatigue is a common and troubling
symptom for people with multiple sclerosis (MS).
Aim To evaluate the effectiveness and cost-effectiveness
of a six-session group-based programme for managing
MS-fatigue (Fatigue: Applying Cognitive behavioural and
Energy effectiveness Techniques to lifeStyle (FACETS)).
Methods Three-centre parallel arm randomised
controlled trial with economic evaluation. Patients with
MS and signiﬁcant fatigue were randomised to FACETS
plus current local practice (FACETS) or current local
practice alone (CLP), using concealed computer-
generated randomisation. Participant blinding was not
possible. Primary outcomes were fatigue severity (Fatigue
Assessment Instrument), self-efﬁcacy (Multiple Sclerosis-
Fatigue Self-Efﬁcacy) and disease-speciﬁc quality of life
(Multiple Sclerosis Impact Scale (MSIS-29)) at 1 and
4 months postintervention (follow-up 1 and 2). Quality
adjusted life years (QALYs) were calculated (EuroQoL 5-
Dimensions questionnaire and the Short-form 6-
Dimensions questionnaire).
Results Between May 2008 and November 2009,
164 patients were randomised; primary outcome data
were available for 146 (89%). Statistically signiﬁcant
differences favour the intervention group on fatigue self-
efﬁcacy at follow-up 1 (mean difference (MD) 9, 95% CI
(4 to 14), standardised effect size (SES) 0.54, p=0.001)
and follow-up 2 (MD 6, 95% CI (0 to 12), SES 0.36,
p=0.05) and fatigue severity at follow-up 2 (MD −0.36,
95% CI (−0.63 to −0.08), SES −0.35, p=0.01) but no
differences for MSIS-29 or QALYs. No adverse events
reported. Estimated cost per person for FACETS is £453;
ﬁndings suggest an incremental cost-effectiveness ratio
of £2157 per additional person with a clinically
signiﬁcant improvement in fatigue.
Conclusions FACETS is effective in reducing fatigue
severity and increasing fatigue self-efﬁcacy. However, it
is difﬁcult to assess the additional cost in terms of cost-
effectiveness (ie, cost per QALY) as improvements in
fatigue are not reﬂected in the QALY outcomes, with no
signiﬁcant differences between FACETS and CLP. The
strengths of this trial are its pragmatic nature and high
external validity.
Trial registration: Current Controlled Trials
ISRCTN76517470.
INTRODUCTION
Fatigue is one of the most commonly reported and
disabling symptoms of multiple sclerosis (MS);1
65% of people with MS consider it one of their
three most troubling symptoms.2 MS-fatigue differs
from tiredness experienced by healthy people in
both severity and impact. It can have a profound
impact on individuals’ lives; limiting or preventing
participation in everyday activities, work, leisure
and social pursuits; and reducing psychological
well-being.3 It is one of the key precipitants of
early retirement4 and its ‘invisible’ nature can make
it difﬁcult for others to understand.5 The patho-
physiology of fatigue is unclear but likely to be
multi-factorial.6
In North America treatments such as energy
effectiveness approaches have been shown to be
moderately helpful.7 8 A systematic review of the
treatment of fatigue in MS highlighted a lack of
high quality studies, particularly those evaluating
psychological and psychosocial approaches.9
Although the important relationships between
physical and psychological aspects of MS-fatigue
are recognised,10 to date there has been just one
trial that has used a cognitive behavioural approach
to managing fatigue in people with MS.11 The
intervention consisted of one-to-one clinical
psychologist-delivered cognitive behavioural
therapy and was shown to be effective in reducing
fatigue. However, in the UK National Health
Service (NHS) and elsewhere, psychologists
working with people with MS are scarce, and thus
this approach may prove impractical.12
We developed a group-based manualised inter-
vention for the management of MS-fatigue
(Fatigue: Applying Cognitive behavioural and
Energy effectiveness Techniques to lifeStyle
(FACETS)).13 The FACETS intervention uses health
professionals routinely involved in managing MS,
supported by a clinical psychologist. This pragmatic
two parallel arm multi-centre randomised con-
trolled trial (RCT) is a formal evaluation of the
effectiveness and cost-effectiveness of FACETS
when added to current local practice.14
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METHODS
The trial was overseen by a steering committee and is reported
in accordance with the Consolidated Standards of Reporting
Trials guidelines for non-pharmacological trials.15 Ethical
approval was obtained from the South West-Central Bristol
Research Ethics Committee (ref: 08/H0106/2). All participants
gave written informed consent before taking part. The trial
sponsor was Poole Hospital NHS Foundation Trust.
The main inclusion criteria were: (1) clinically deﬁnite MS
diagnosis, (2) fatigue impacting on daily life (Fatigue Severity
Scale total score >4)16 and (3) ambulatory. The main exclusion
criteria were: (1) having taken part in a fatigue programme in
the last year, (2) cognitive impairments, (3) a relapse in the pre-
vious 3 months or (4) having started treatment with disease
modifying or antidepressant drugs within the previous
3 months. The full eligibility criteria are described in the proto-
col.14 Participants were recruited in three UK centres (Poole,
Bristol, Southampton/Portsmouth) from primary or secondary
care, or via MS Society newsletters/websites. Recruitment took
place from May 2008 to November 2009.
Intervention (FACETS)
The manualised group-based FACETS programme is described
elsewhere13 and is based upon a conceptual framework integrat-
ing elements from cognitive behavioural, social-cognitive,
energy effectiveness, self-management and self-efﬁcacy theories.
The aim of the intervention is to help people normalise their
fatigue experiences, learn helpful ways of thinking about fatigue
and use available energy more effectively. The intervention con-
sists of six sessions (∼90 min duration) held weekly and facili-
tated in groups of 6–12 by two health professionals with
experience of working with people with MS and group-work
(such as occupational therapists, nurses or physiotherapists).
The intervention is highly structured. Each session follows
the same general format, namely, facilitator-delivered presenta-
tions, ﬂipchart discussions, group activities and homework.
The facilitator manual provides guidance on preparation and
delivery, detailed session content, notes and suggested timings,
and a checklist of facilitator objectives as well as signposts to
additional resources. Sessions are delivered via PowerPoint;
hence can be easily replicated. A companion participant hand-
book, along with existing information booklets, reinforces pro-
gramme content. The incorporation of ﬂipchart exercises, group
discussions and homework activities enables the tailoring of
content to the individual circumstances and goals/priorities of
group members. Participants receiving the intervention contin-
ued to have access to services available as part of their usual
local care.
FACETS was delivered in hotel meeting-room facilities, with
the exception of one centre, where it was held in a rehabilitation
hospital. Apart from one MS specialist nurse, facilitators were
either occupational therapists or physiotherapists. Facilitators
were all qualiﬁed to a senior/advanced level (in the UK
minimum of a Band 7 on the NHS Agenda for Change (AfC)
grading structure).17 Facilitators were trained to deliver the
intervention at 1-day workshops and psychological advice and
debrieﬁng were available for facilitators throughout the trial.
Prior to this full scale trial, we carried out a small pilot study
(n=18) delivering the group-based intervention once in each of
the three centres (Poole, Bristol, Southampton) and collecting
preoutcome and postoutcome measurements. This enabled us to
test trial procedures, check clarity of and adherence to the
manual and explore transferability of the intervention.
Current local practice
Participants randomised to the CLP arm of the trial received
current local practice only. This could have ranged from general
advice and information provision about MS-fatigue to more
detailed individualised management advice from a variety of
health professionals. Inevitably, there will have been variations
in the exact composition of what was usually provided, within
and between centres, depending on local resources and patient
need. Collecting detailed information at an individual level on
the type and quantity of advice received as part of current local
practice was not deemed feasible. However, we consider this
variation to be a strength of the trial as it increases its applicabil-
ity to a wider range of centres. Individuals who had attended a
fatigue management programme in the past year were excluded
from the trial as were those who had received a fatigue interven-
tion from a health professional in the past 3 months (see proto-
col).14 To increase external validity, no attempt was made in the
FACETS arm to restrict or control participants’ access to current
local practice or to standardise it across healthcare settings or
treatment arms. When we refer to the FACETS arm, participants
in this arm also received current local practice.
To ensure good allocation concealment, random allocation
was email based and administered by the statistician who was
masked to the identity of participants. Randomisation used a
computerised random number generator. Once a block of up to
24 participants from a centre had provided informed consent,
they were formally entered onto the trial database and an anon-
ymised list of their identiﬁcation numbers was sent to the statis-
tician who randomly allocated half to the FACETS arm and half
to the CLP arm.
Masking
The nature of the trial meant that participant blinding was not
possible. All outcomes were self-reported using validated
measures.
Outcome measures
Demographic information collected is reported in table 1.
For those allocated to the FACETS arm, outcomes were mea-
sured 1 week (baseline) before the start of FACETS and
1 month (follow-up 1) and 4 months (follow-up 2) after the
ﬁnal session. Participants assigned to the CLP arm completed all
outcome measures within an identical time frame to those in
the FACETS arm (see published protocol14 and results tables).
All questionnaire outcomes were self-reported for both groups,
presented in a booklet format with a large font and adminis-
tered and returned through the post. This meant that partici-
pants could pace the completion of the outcome measures in
their own homes.
Primary outcome measures
These were: (1) fatigue severity (Global Fatigue Severity (GFS)
subscale of the Fatigue Assessment Instrument (FAI)),18 (2)
disease-speciﬁc quality of life (QOL) (total score on the
Multiple Sclerosis Impact Scale, V.1 (MSIS-29, V.1))19 and (3)
self-efﬁcacy for managing fatigue (Multiple Sclerosis-Fatigue
Self-Efﬁcacy scale—adapted from the Control subscale of the
MS Self-Efﬁcacy scale).20
Secondary outcome measures
See protocol14 and online web supplement for further detail.
These included: (1) subscales of the FAI,18 (2) the Fatigue
Symptom Inventory,21 (3) the Hospital Anxiety and Depression
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Scale,22 (4) the physical and psychological subscales of the
MSIS-29, V.1,19 (5) the Medical Outcomes Short-Form Survey,
V.2 (SF-36v2),23 (6) health state values and quality adjusted life
years (QALYs) derived from the EuroQoL 5-Dimensions
questionnaire (EQ-5D)24 and the Short-form 6-Dimensions
questionnaire (SF-6D),25 (7) self-reported health and social ser-
vices resource utilisation with a 3-month recall period (collected
at follow-up 2 only) and (8) objective measures of physical activ-
ity over a 48 h period (weekday/weekend day) using ActivPAL
accelerometers (total energy expenditure over 48 h period).26
Self-reported feedback was gathered from FACETS partici-
pants immediately after each session via a brief anonymised
semistructured evaluation questionnaire returned in an enve-
lope. Using 5-point scales the dimensions were programme
content (1 ‘not very relevant’, 5 ‘very relevant’), format (1 ‘did
not work at all’, 5 ‘worked well’), usefulness (1 ‘not at all
useful’, 5 ‘very useful’), pace (1 ‘too slow’, 5 ‘too fast’) and dur-
ation (1 ‘too short’, 5 ‘too long’).
Sample size considerations and statistical analysis
The sample size requirement was 146 participants with
follow-up data based on having 85% power to detect a medium
standardised effect size of 0.527 for the primary outcome mea-
sures, using a two-sided 5% signiﬁcance level (see protocol for
justiﬁcation for this medium effect size).14 As a variety of
fatigue measures have been used in other trials, we used standar-
dised effect sizes to enable comparisons between them.
The main analysis was intention-to-treat but we also con-
ducted a ‘per protocol’ analysis (excluding participants who
attended fewer than four FACETS sessions). Data were analysed
using IBM SPSS, V.18. Outcome measures were assumed to be
interval-scaled, and the analysis initially focused on absolute
change in outcomes at follow-up 1 (1 month postintervention)
and at follow-up 2 (4 months postintervention), relative to base-
line. Change scores were compared between the groups using
the independent samples t test with a two-sided 5% signiﬁcance
level, and summarised using mean differences (95% CIs). The
GFS primary outcome is probably the most clinically relevant
and so for this outcome we have also deﬁned a clinically import-
ant improvement in fatigue as 0.5 and used the
numbers-needed-to-treat statistic and the χ2 test for association
to compare the percentage with a clinically important improve-
ment between the two arms of the trial. This ﬁgure of 0.5 is
equivalent to approximately 0.5 SDs which was the effect size
speciﬁed in the sample size calculation and recommended by
others.28 We could not ﬁnd any published, minimal clinically
important differences (MCIDs) for the GFS subscale of the FAI
in MS. However, an MCID of -0.6 points has been reported for
the Fatigue Severity Scale (which shares eight of the nine GFS
items, in addition to three additional ones) for systemic lupus
erythematosus.29
As detailed in the protocol,14 additional prespeciﬁed supple-
mentary analyses also (a) adjusted for baseline variability/base-
line differences between treatment arms (baseline measurement,
the baseline primary outcome measurements, gender, age,
marital status, education level, type of MS, time since diagnosis
and level of disability), (b) adjusted for any clustering effects
arising from the group-based nature of FACETS using multilevel
modelling,30 (c) assessed the impact of missing data31 using two
approaches (the ‘Last Observation Carried Forward’ imputation
method (which assumes no change in outcome when a data
point is missing) and a mixed model approach for analysing
repeated measurements) and (d) modelled all measurement
occasions together for each outcome using repeated measures
analysis of variance. To further aid interpretation, for primary
outcomes we have also run multilevel models that include all
Table 1 Descriptive statistics for demographic and baseline
characteristics of participants
FACETS
(n=84)
CLP
(n=80)
Gender (n (%))
Female 61 (73%) 58 (73%)
Male 23 (27%) 22 (28%)
Age (years)
Mean (SD) 48.0 (10.2) 50.1 (9.1)
Range 23–73 28–70
Ethnicity (n (%))
White English 68 (85%) 69 (92%)
White British 7 (9%) 5 (7%)
Other 5 (6%) 1 (1%)
Not stated 4 5
Self-reported disease type (n (%))
Benign 4 (5%) 2 (3%)
Relapsing-remitting 35 (43%) 40 (51%)
Secondary progressive 16 (20%) 23 (29%)
Primary progressive 5 (6%) 8 (10%)
‘Don’t know’ 21 (26%) 5 (6%)
Not stated 3 2
APDDS score (Adapted Patient Determined Disease Steps) (n (%))
3 or less (no limitations on walking) 18 (22%) 15 (19%)
4 or 5 (MS interferes with walking) 37 (46%) 42 (54%)
6 or more (At min., needs stick/crutch to walk
100 m)
26 (32%) 21 (27%)
Not stated 3 2
Level of education (n (%))
Highest qualification achieved
No qualifications 8 (10%) 8 (10%)
One or more GCSE (or equivalent) 36 (46%) 29 (38%)
One or more A level (or equivalent) 10 (13%) 12 (16%)
First degree (or equivalent) 16 (20%) 19 (25%)
Higher degree/professional qualification 9 (11%) 8 (11%)
Not stated 5 4
Employment status (n (%))
In full-time employment (>30 h per week) 15 (18%) 11 (14%)
In part-time employment (≤30 h per week) 11 (14%) 13 (17%)
Self-employed 4 (5%) 4 (5%)
Not in paid employment (unemployed, in
education, retired, looking after home)
51 (63%) 50 (64%)
Not stated 3 2
Marital status (n (%))
Married/cohabiting 63 (78%) 54 (71%)
Single 5 (6%) 7 (9%)
Separated/divorced 9 (11%) 14 (18%)
Widowed 4 (5%) 1 (1%)
Not stated 3 4
Years since diagnosis (n (%))
<1 year 2 (3%) 4 (5%)
1–5 years 32 (40%) 21 (27%)
6–10 years 13 (16%) 19 (24%)
11–15 years 21 (26%) 12 (15%)
≥16 years 12 (15%) 22 (28%)
Not stated 4 2
Percentages rounded to nearest integer and, thus, might not sum exactly to 100%.
CLP, current local practice; FACETS, Fatigue: Applying Cognitive behavioural and
Energy effectiveness Techniques to lifeStyle; GCSE, General Certificate of Secondary
Education; MS, multiple sclerosis.
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time points, all baseline variables listed previously, study site and
clustering effects.
Energy expenditures over 48 h were calculated based on the
default values of the ActivPAL software package. Provided at
least 24 h data were available, missing data were replaced by
data from this period.
Economic evaluation
Cost-effectiveness analyses were undertaken from the perspective
of the NHS and personal social service provider (Third Party
Payer), assessing the mean incremental cost for delivery of the
intervention against the effectiveness of the intervention. The
primary economic endpoint is presented in cost-effectiveness
analysis as the cost per unit change in GFS and also in the more
policy relevant context of cost per additional person with a clin-
ically signiﬁcant improvement in fatigue. Secondary analysis esti-
mates QALYs using the EQ-5D and SF-36 (SF-6D) and sets out
ﬁndings against a cost-utility analysis. EQ-5D is used as the prin-
cipal QALY measure, with SF-6D used for sensitivity analysis.
QALYs were calculated over the 24-week period from baseline to
follow-up 2 (0.46 years) using the area under the curve
method.32 It is current convention to adjust between group dif-
ferences in QALYs for baseline values of EQ-5D/SF-6D.33
Intervention costs for delivery of the FACETS programme are
based on within-trial data including work sampling forms com-
pleted by clinical staff who delivered the programme. A mean
net cost per participant is estimated, reﬂecting an incremental
cost per participant. Costs were estimated using pounds sterling
at 2010 unit costs. The analysis is short-term, within the trial
follow-up period, and no discounting of future costs or effects
is required. Sensitivity analyses have been undertaken to address
key areas of uncertainty within the estimates of the intervention
cost, and on assumptions included in cost estimates.
Healthcare service use data and unit cost data were combined
to estimate mean healthcare costs over a 3-month period (the
3 months prior to follow-up 2) in each trial arm. Unit cost data
associated with the use of health and social services in the
3 months prior to follow-up 2 were obtained from credible
national sources (Personal Social Services Research Unit,34 NHS
Reference costs,35 local NHS Trust cost data) (see online supple-
mentary table S1). Non-parametric bootstrapping methods were
used to estimate CIs around cost estimates for healthcare service
use (see the trial protocol for further detail on methods).14
RESULTS
A total of 164 people were randomised (nine from primary
care) (ﬁgure 1). First follow-up data are available for 146 (89%)
and second follow-up for 144 (88%). Recruitment was 39 from
the Bristol centre, 75 from the Southampton/Portsmouth Centre
and 50 from the Poole centre. In all, 84 participants were ran-
domised to FACETS and 80 to CLP. Overall, 10 FACETS pro-
grammes were run with group sizes ranging from 4 to 11
(mean=7.4; SD=2.1). The percentage of participants attending
individual sessions ranged from 70% (Session 5) to 81%
(Session 1). A total of 72 (86%) attended ≥ 4 sessions and 66
(79%) attended the ﬁnal session (see online supplementary
tables S2a and S2b). The reasons for non-attendance are
reported in ﬁgure 1.
At baseline, distributions of the descriptive statistics for the
trial sample look mostly similar (table 1); since allocation was
random any differences are due to chance.36 37 Table 2 and the
online supplementary table S3 present descriptive statistics for
the primary and secondary outcome measures, respectively, at
baseline and follow-up.
Primary outcomes
The primary ‘intention-to-treat’ analyses and results for the
primary outcome measures are shown in table 2 and online sup-
plementary ﬁgure S1. There were statistically signiﬁcantly
greater improvements in fatigue self-efﬁcacy in the FACETS arm
at follow-up 1 and 2 compared with the CLP arm. By follow-up
2, there were signiﬁcantly greater improvements on the GFS
scale in the FACETS arm compared with the CLP arm. Further,
40% of participants in the FACETS arm had a clinically import-
ant improvement on the GFS compared with 19% in the CLP
arm (p=0.009), giving a numbers-needed-to-treat of 5. There
were no statistically signiﬁcant differences between the FACETS
arm and the CLP arm for the MSIS-29. The probability of
getting three or more statistically signiﬁcant differences out of
six tests on the primary outcomes, just by chance, is only 0.002.
Prespeciﬁed supplementary analyses showed that the results
for the primary outcome measures were unaltered (ie, those that
were statistically signiﬁcant remained) by (a) adjusting for pre-
speciﬁed baseline characteristics and centre (with the exception
of fatigue self-efﬁcacy at 4 months (follow-up 2), where mean
difference reduced from 6 to 4 (−2, 10), p=0.15), (b) adjusting
for clustering, (c) using different strategies for dealing with
missing data and (d) analysing all time points together using a
repeated measures model.
Overall multilevel models incorporating clustering, baseline
characteristics and repeated measures showed a signiﬁcant main
effect for fatigue self-efﬁcacy (mean difference 6.2 (95% CI 1.7
to 10.7)), with no interaction (ie, no evidence that the effect at
4 months is less than the effect at 1 month), a signiﬁcant inter-
action for the GFS (p=0.006), whereby the difference between
the trial arms at 4 months is greater than at 1 month, and no
signiﬁcant difference for MSIS-29 total score. The per protocol
results (including only those who attended ≥4 FACETS sessions)
for the primary outcomes were essentially the same as for the
intention-to-treat analysis (ie, there was no impact on whether
or not differences were statistically signiﬁcant).
Adverse events
No adverse events, as deﬁned in the protocol, were reported.
Secondary outcomes
Consistent with the results for the primary outcome measures,
there were statistically signiﬁcantly greater improvements in the
secondary outcome measures of ‘average fatigue’ at follow-up 1
and 2, and ‘fatigue right now’ at follow-up 1 in the FACETS
arm compared with the CLP arm (see online supplementary
table S3). Further, there were greater improvements in the
Vitality subscale of the SF-36 in the FACETS arm than the CLP
arm at follow-up 2. In prespeciﬁed supplementary analyses, the
differences seen at follow-up 2 were robust when analysed in a
variety of ways, as outlined in the previous section. However, at
follow-up 1 the mean difference (95% CI) in ‘average fatigue’
was reduced from −0.71 to −0.40 (-0.94 to 0.14), p=0.14 and
for ‘fatigue right now’ from −0.99 to −0.39 (−1.19 to 0.41),
p=0.33 when we controlled for the prespeciﬁed baseline char-
acteristics and centre.
There were no statistically signiﬁcant differences between the
FACETS and CLP arms at either follow-up on the MSIS-29 sub-
scales, the Hospital Anxiety and Depression Scale, the SF-36
subscales (with the exception of ‘Vitality’) or the EQ-5D and
SF-6D. There were also no statistically signiﬁcant differences in
activity levels (ActivPAL data) between the two arms at either
follow-up.
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Session evaluation questionnaires
Out of a total of 388 session attendances, questionnaires were
completed and returned for 97%. Mean (SD) scores (on 1–5
scale, 5=ideal) were 4.6 (0.6) for content, 4.5 (0.7) for format,
4.6 (0.7) for usefulness and (on 1–5 scale, 3=ideal) 3.3 (0.6)
for pace and 3.1 (0.6) for length (see online supplementary
table S4).
Economic analysis
The estimated cost per iteration of FACETS is £3625 (see online
supplementary table S5). Assuming a mean group size of eight,
the mean cost per participant per FACETS programme is £453
(£518 per participant, assuming seven participants per iter-
ation). A primary area of uncertainty in this estimate is the level
of staff input time for programme delivery (mean (SD) 56.63
(14.74) h). Using probabilistic sampling from this distribution,
in 95% of samples the estimates of intervention cost range from
£331 to £585 per participant. Assuming costs are based on
input from less experienced (less-costly) health professionals
(one NHS National Payscale AfC Band 7 therapist and one AfC
Band 5 therapist, instead of two AfC Band 7 therapists),17 the
estimated mean cost per participant is £414, with 95% of esti-
mates in the range of £311–£526 per participant.
For cost-effectiveness analysis against GFS outcome, the incre-
mental cost-effectiveness ratio was £1259 per 1-point improve-
ment in fatigue (cost/measure of effect), or in a more policy
relevant context £2157 per additional person with a clinically
signiﬁcant improvement in fatigue (GFS). There were no
Figure 1 Flowchart showing study participation.
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statistically signiﬁcant differences between arms in EQ-5D or
SF-36 (SF-6D) health state values. Observed differences in
QALYs favour the CLP arm, but these are small, and not statis-
tically signiﬁcant. Thus, in the context of the cost per QALY
data ﬁndings (summary statistic), CLP dominates FACETS; that
is, it costs less with equal or greater beneﬁt in QALYs. Average
costs for healthcare utilisation for the FACETS arm were
approximately £50 higher, although this difference was not stat-
istically signiﬁcant (see online supplementary table S6).
DISCUSSION
A novel fatigue management programme (FACETS) for people
with MS is effective in reducing fatigue severity and increasing
fatigue self-efﬁcacy. Standardised effect sizes were small-to-
medium. Improvements in fatigue severity were not apparent
until follow-up 2 (4 months post intervention); changes in atti-
tudes and lifestyle central to the programme are likely to take
time to incorporate into daily routines. It may take longer still
for these changes to impact on QOL and longer term follow-up
would be required to explore this further. The ActivPAL data
(see online supplementary table S3) suggest that reduced fatigue
severity in the FACETS arm was not primarily achieved via
diminished activity levels. Improvements in fatigue self-efﬁcacy,
while signiﬁcant at ﬁrst follow-up, were only marginally so at
follow-up 2, and did not remain signiﬁcant after supplementary
analyses adjusting for prespeciﬁed baseline variables and centre.
Relative to the CLP arm, there were no changes in disease-
speciﬁc QOL. Ratings on evaluation questionnaires indicated
high overall satisfaction, and combined with high attendance
rates, suggested the programme was well received.
The estimated additional cost for FACETS is modest at £453,
and it has shown an important difference in the proportion of
patients with a clinically signiﬁcant improvement in fatigue
(GFS) as well as improvements on the Vitality subscale of the
SF-36 and in fatigue self-efﬁcacy. However, the cost-
effectiveness case is equivocal as it is difﬁcult to interpret these
beneﬁts in the context of overall health related QOL, given the
absence of evidence in the trial to support QALY gains. Given
the paucity of treatment options for fatigue in MS, the FACETS
intervention may present as a value for money intervention. We
suggest that decision-makers may be persuaded by the potential
for FACETS to be cost-effective as at the estimated cost for
FACETS it would only take a small incremental change in
QALYs (a change of 0.015 QALYs) to indicate the intervention
was cost-effective at a cost per QALY threshold commonly
applied in the UK National Institute for Health and Clinical
Excellence setting. The evidence from the current trial is
unclear, and we discuss this further below.
The only other RCT to explore the effectiveness of a cogni-
tive behavioural approach for the management of MS-fatigue
took place in New Zealand.11 This trial differed from ours in
that it involved one-to-one cognitive behavioural therapy deliv-
ered by one clinical psychologist in a single centre to relatively
small numbers of people with MS and had an active comparator
(relaxation) and used a different measure of fatigue. This makes
direct comparison of the results problematic. In a health service
like the UK NHS where psychologists working with people with
MS are scarce, this approach may prove impractical.
Strengths and limitations
This is the largest RCT to explore a cognitive behavioural
approach to fatigue management for people with MS. Trial
quality was high in that treatment allocation was concealed, the
recruitment target met and sample attrition low. A key strength
of this trial is its pragmatic nature and high external validity: the
programme was compared against what is currently happening
in the NHS, in a variety of locations, and was mostly delivered
by individuals not involved in developing the programme but
practising clinically. It thus offers a test of the intervention in an
environment very close to real clinical practice. Effect sizes were
modest but pragmatic trials generally yield smaller effect sizes
than tightly controlled RCTs. Given the high prevalence of
fatigue in MS and its debilitating impact, small/medium
improvements may be important.
Table 2 Descriptive statistics and treatment effects for the primary outcome measures
Outcome measure Baseline (n=159) Follow-up 1 (n=146) Follow-up 2 (n=144)
Global Fatigue Severity subscale of the Fatigue Assessment Instrument (potential range 1–7, high scores indicate more fatigue)
FACETS mean (SD) 5.60 (0.98) 5.48 (0.92) 5.26 (1.03)
CLP mean (SD) 5.61 (1.09) 5.55 (1.17) 5.66 (0.93)
Mean diff in change from baseline (95% CI)* – −0.03 (−0.33 to 0.28) −0.36 (−0.63 to −0.08)
p Value – 0.86 0.01
Std effect size – −0.03 −0.35
Multiple Sclerosis Impact Scale-29 (potential range 0–100, high scores indicate more impact)
FACETS mean (SD) 49.6 (19.1) 47.3 (18.2) 44.9 (19.2)
CLP mean (SD) 43.9 (17.6) 42.2 (18.4) 43.0 (17.3)
Mean diff in change from baseline (95% CI)* – 1.44 (−2.36 to 5.24) −1.56 (−6.45 to 3.34)
p Value – 0.46 0.53
Std effect size – 0.08 –0.08
Fatigue Self-Efficacy Scale (potential range 10–100, high scores indicate more certainty in controlling fatigue)
FACETS mean (SD) 45 (17) 57 (17) 56 (19)
CLP mean (SD) 49 (16) 50 (17) 53 (17)
Mean diff in change from baseline (95% CI)* – 9 (4 to 14) 6 (0 to 12)
p Value – 0.001 0.048
Std effect size – 0.54 0.36
*Mean difference at follow-up can be thought of as mean in FACETS arm – mean in CLP arm (after subtracting any baseline differences). Analysis only includes participants with both
baseline and follow-up data).
CLP, current local practice; FACETS, Fatigue: Applying Cognitive behavioural and Energy effectiveness Techniques to lifeStyle.
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We were not able to assess the representativeness of the
sample by comparing trial participant characteristics with those
who were not recruited as these data were not collected for the
latter group. It is possible that there might have been a recruit-
ment bias towards individuals who were more amenable to a
non-pharmacological approach.
A potential criticism of pragmatic trials such as ours is that the
FACETS arm received more health professional contact, time and
attention than the CLP arm and it might be this, rather than pro-
gramme content, which produced improvements. However,
despite considering outcomes covering a range of dimensions,
only those speciﬁcally related to the purpose of the FACETS pro-
gramme (ie, fatigue and fatigue self-efﬁcacy) were statistically sig-
niﬁcant. If there was an impact of attention, one could
hypothesise the observed differences would be less focused.
In keeping with the pragmatic nature of this trial, to increase
external validity no attempt was made to restrict or control trial
participants’ access to current local practice or to standardise it
across healthcare settings or treatment arms. In none of the
centres was best practice to do nothing; participants will have
received a variety of advice depending on local service/individ-
ual need. Collecting accurate detailed information at an individ-
ual level on the type/quantity of advice received as part of
current local practice was outside the scope of the trial and is
therefore a limitation.
We did not formally assess treatment ﬁdelity. Measuring ﬁdelity
would have required either having an observer or audio-/
video-recording sessions and these approaches can impact on parti-
cipants’ willingness to participate in research and on the dynamics
of group sessions. FACETS is manualised with a detailed descrip-
tion of content to be delivered, a suggested script for facilitators,
guidance notes and a detailed checklist of key aspects to be
covered. Observations of sessions, feedback from the facilitators
during the three centre pilot study, facilitators’ debriefs and evalu-
ation of participant feedback on each session suggested that the
intervention was being delivered as intended.
We acknowledge that specifying three primary outcomes and
two follow-up points (ie, six tests) inﬂates the risk of a Type I
error. However, the probability of obtaining statistically signiﬁ-
cant differences on 3/6 tests (independent) by chance is very
small (p=0.002) and supplementary analysis using repeated mea-
sures analysis of variance to analyse all time points together did
not affect the ﬁndings. The follow-up period in this trial was rela-
tively short (4 months). Longer follow-up periods would be
needed to assess the longevity of the results. The FACETS pro-
gramme encourages changes in behaviour and thinking which, if
maintained, have the potential for longer term beneﬁt.
In the UK NHS and elsewhere, cost per QALY is a common
basis for decision-making related to funding healthcare interven-
tions.38–40 The QALY data here indicate no statistically signiﬁ-
cant difference between the trial arms, and a trend towards CLP
dominating FACETS (ie, the latter costs more and has equal or
slightly less beneﬁt in QALYs). However, there is some basis for
being cautious about these ﬁndings, and for considering the
potential for FACETS to offer a cost-effectiveness proﬁle that
may be attractive to decision-makers, as there is a difference in
effectiveness for fatigue, a key aspect of patient reported
outcome, even though it is not reﬂected in the QALY outcomes.
There is a growing evidence base to suggest that the EQ-5D and
SF-36 generic measures may lack both relevance and sensitivity
to changes in health related QOL in MS. These measures,
although widely used, may not address important areas of
impact speciﬁc to MS, most notably fatigue,41–44 and both have
been found to lack responsiveness.45 The relatively small sample
size in the current study could have contributed to the insensi-
tivity of QALY measures to differences in fatigue. Recent
research on condition-speciﬁc preference-based measures for
MS, using a large observational study, has indicated that where
there is an improvement in MSIS-29 subscale scores (as seen in
the current study although not statistically signiﬁcant), there is
likely to be a QALY gain.42 Therefore, it may be that FACETS
does have the potential to demonstrate QALY gains, although
the current study has not presented evidence of this using the
generic health status measures.
This intervention could be a clinically useful, relatively inex-
pensive addition to current local practice in appropriate hos-
pital/community settings. It could be readily incorporated into
existing services, facilitating the integration of psychology-based
approaches into patient care.
Correction notice This paper has been amended since it was published Online
First. The legend for ﬁgure 1 has been incorrectly titled. Originally it was written as
follows: “Mean differences and 95% CIs on the primary outcomes at baseline,
follow-up 1 (1 month postintervention) and follow-up 2 (4 months postintervention).
CLP, current local practice; FACETS, Fatigue: Applying Cognitive behavioural and
Energy effectiveness Techniques to lifeStyle.” It has now been corrected to the
following legend: “Flowchart showing study participation.”
Acknowledgements Thanks to all the participants who took part and to the
clinicians who identiﬁed the potential participants for the trial. Thanks to Ms Felicity
Burgess for supporting recruitment at the Southampton centre. Thanks to Dr Sara
Demain, Mrs Caroline Birch, Ms Charlie Ewer-Smith, Mrs Jo Kileff, Mrs Jenn Gash
and Mrs Sheila Chartres for delivering the FACETS Programme. Thanks to Dr Reuben
Ogollah for data extraction from the ActivPALs™. Thanks to Mr Geoff Linder and
Mr Tim Worner for patient and public involvement. Thanks to Mrs Chris Richards,
Mrs Moira Hawey and Mrs Louise Ward for data entry. Thanks for support from the
Comprehensive Clinical Research Network and the Primary Care Network. Thanks to
Ms Sally Johnson for contributing to facilitation of the FACETS programme during
the pilot work.
Contributors ST: conception, design, acquisition of data, analysis, interpretation,
drafted article. PT: chief investigator, conception, design, analysis, interpretation,
drafted article. PK and RJ: design, acquisition of data, interpretation, critically
reviewed article. CG: design, analysis, interpretation, drafted economic aspects,
critically reviewed article. AN and VS: design, delivered fatigue management
programme, acquisition of data, interpretation, critically reviewed article. ADS:
design, delivered fatigue management programme, critically reviewed article. RB and
KTG: design, interpretation, critically reviewed article. CH: design, clinical overview of
trial, interpretation, critically reviewed article.
Funding This research was funded by the Multiple Sclerosis Society of Great Britain
and Northern Ireland (Grant number 846/06).
Competing interests All authors have completed the Uniﬁed Competing Interests
form at http://www.icmje.org/coi_disclosure.pdf (available on request from the
corresponding author) and declare: all authors had ﬁnancial support from the
Multiple Sclerosis Society of Great Britain and Northern Ireland for the submitted
work; no ﬁnancial relationships with any organisations that might have an interest in
the submitted work in the previous 3 years. RB is the chair of the MS Society Grant
Review Panel for Care and Services Research. PT and CG are members of the MS
Society Grant Review Panel for Care and Services Research. PT is a member of the
Advisory Board for the Sativex Registry. The Board provides an independent review
of safety data for patients prescribed Sativex. Bournemouth University receives a fee
from GW Pharma to cover time spent at meetings, and travel expenses.
Patient consent Obtained.
Ethics approval South West-Central Bristol Research Ethics Committee
(ref: 08/H0106/2).
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Krupp LB, Seraﬁn DJ, Christodoulouu C. Multiple sclerosis-associated fatigue. Expert
Rev Neurother 2010;10:1437–47.
1098 Thomas S, et al. J Neurol Neurosurg Psychiatry 2013;84:1092–1099. doi:10.1136/jnnp-2012-303816
Multiple sclerosis
 o
n
 3 M
ay 2018 by guest. Protected by copyright.
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2012-303816 on 21 May 2013. Downloaded from 
2 Branas P, Jordan RE, Fry-Smith A, et al. Treatments for fatigue in multiple sclerosis:
a rapid and systematic review. Health Technol Ass 2000;4:1–61.
3 Costello K, Harris C. Differential diagnosis and management of fatigue in multiple
sclerosis: considerations for the nurse. J Neurosci Nurs 2003;35:139–48.
4 Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life
consequences of multiple sclerosis. Mult Scler 2000;6:91–8.
5 White CP, White MB, Russell CS. Invisible and visible symptoms of multiple sclerosis:
which are more predictive of health distress? J Neurosci Nurs 2008;40:85–95.
6 Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and
management. Mult Scler 2003;9:219–27.
7 Mathiowetz VG, Matuska KM, Finlayson ML, et al. One-year follow-up to a
randomized controlled trial of an energy conservation course for persons with
multiple sclerosis. Int J Rehabil Res 2007;30:305–13.
8 Blikman LJ, Huisstede BM, Koojimans H, et al. Effectiveness of energy conservation
treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-
analysis. Arch Phys Med Rehabil Published Online First: 11 Feb 2013. doi:10.1016/
j.apmr.2013.01.025
9 Lee D, Newell R, Ziegler L, et al. Treatment of fatigue in multiple sclerosis: a
systematic review of the literature. Int J Nurs Pract 2008;14:81–93.
10 van Kessel K, Moss-Morris R: Understanding multiple sclerosis fatigue: a synthesis
of biological and psychological factors. J Psychosom Res 2006;61:583–5.
11 van Kessel K, Moss-Morris R, Willoughby E, et al. A Randomized controlled trial of
cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med
2008;70:205–13.
12 Thomas PW, Thomas S, Hillier C, et al. Psychological interventions for multiple
sclerosis. Cochrane Database Syst Rev 2006;1:CD004431. doi: 10.1002/14651858.
CD004431.pub2
13 Thomas S, Thomas PW, Nock A, et al. Development and preliminary evaluation of a
cognitive behavioural approach to fatigue management in people with multiple
sclerosis. Patient Educ Couns 2010;78;204–10.
14 Thomas PW, Thomas S, Kersten P, et al. Multi-centre parallel arm randomised
controlled trial to assess the effectiveness and cost-effectiveness of a group-based
cognitive behavioural approach to managing fatigue in people with multiple
sclerosis BMC Neurol 2010;10:43.
15 Boutron I, Moher D, Altman DG, et al.; for the CONSORT group. Extending the
CONSORT Statement to randomized trials of nonpharmacologic treatment:
explanation and elaboration. Ann Intern Med 2008;148:295–309.
16 Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to
patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol
1989;10:1121–3.
17 NHS Careers. Pay and beneﬁts for AHP staff. http://www.nhscareers.nhs.uk/explore-
by-career/allied-health-professions/pay-and-beneﬁts-for-ahp-staff/ (accessed
30 Dec 2012).
18 Schwartz JE, Jandorf L, Krupp L. The measurement of fatigue: a new instrument.
J Psychosom Res 1993;37:753–62.
19 Hobart JC, Riazi A, Lamping D, et al. Improving the evaluation of therapeutic
interventions in multiple sclerosis: development of a patient-based measure of
outcome. Health Technol Assess 2004;8:1–60.
20 Schwartz CE, Coulthard-Morris L, Zeng Q, et al. Measuring self-efﬁcacy in people
with multiple sclerosis: a validation study. Arch Phys Med Rehabil 1996;77:394–8.
21 Hann D, Jacobsen P, Azzarello L, et al. Measurement of fatigue in cancer patients:
Development and validation of the Fatigue Symptom Inventory. Qual Life Res
1998;7:301–10.
22 Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Neurol
Scand 1983;67:361–70.
23 Ware JE, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36):I.
Conceptual framework and item selection. Med Care 1992;30:473–83.
24 Dolan P. Modeling Valuations for EuroQol Health States. Med Care
1997;35:1095–108.
25 Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of
health from the SF-36. J Health Econ 2002;21:271–92.
26 Ryan CG, Grant PM, Tigbe WW, et al. The validity and reliability of a novel activity
monitor as a measure of walking. Br J Sports Med 2006;40:779–84.
27 Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale:
NJ Lawrence Erlbaum Associates, 1988.
28 Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality
of life. The remarkable universality of half a standard deviation. Med Care
2003;41:582–92.
29 Goligher EC, Pouchot J, Brant R, et al. Minimal clinically important difference for
7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol
2008;35:635–42.
30 Bauer DJ, Sterba SK, Hallford DD. Evaluating group based interventions when
control participants are ungrouped. Multivar Behav Res 2008;43:210–36.
31 Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF
and MMRM approaches. Pharm Stat 2008;7:93–106.
32 Brazier JE, Ratcliffe J, Salomon A, et al. Measuring and valuing health for economic
evaluation. Oxford: Oxford University Press, 2007.
33 Manca A, Hawkins N, Sculpher M. Estimating mean QALYs in trial-based cost
effectiveness analysis: the importance of controlling for baseline utility. Health Econ
2005;4:87–496.
34 Curtis L. Unit costs of health and social care. Personal social services research unit
(PSSRU), Canterbury. UK: University of Kent, 2010.
35 Department of Health. NHS Reference Costs 2009-2010, 2011. http://www.dh.gov.
uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/
DH_123459 (accessed 30 Dec 2012).
36 CONSORT Statement website. http://www.consort-statement.org/consort-statement/
13-19–-results/item15_baseline-data/ (accessed 7 Mar 2013).
37 Altman DG, Doré CJ. Randomisation and baseline comparisons in clinical trials.
Lancet 1990;335:149–53.
38 National Institute for Health and Clinical Excellence (NICE). Guide to the methods
of technology appraisal. London, UK: NICE, June 2008.
39 Australian Government Department of Health and Ageing. Pharmaceutical Beneﬁts
Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical
Beneﬁts Advisory Committee (Version 4.3). Barton, Australia: Australian
Government. Department of Health and Ageing, December 2008.
40 Canadian Agency for Drugs and Technologies in Health. Guidelines for the
economic evaluation of health technologies: Canada, 3rd edn. Ottawa: Canadian
Agency for Drugs and Technologies in Health, 2006.
41 Hemmett L, Holmes J, Barnes M, et al. What drives quality of life in multiple
sclerosis? Q J Med 2004;97:671–6.
42 Hobart J, Freeman J, Lamping D, et al. The SF-36 in multiple sclerosis: why
assumptions must be tested. J Neurol Neurosurg Psychiatry 2001;71:363–93.
43 Opara JA, Jaracz K, Brola W. Quality of life in multiple sclerosis. J Med Life
2010;3:352–8.
44 Fisk JD, Brown MG, Sketris IS, et al. A comparison of health utility measures for the
evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry
2005;76:58–63.
45 Hawton A, Green C, Telford C, et al. Using the Multiple Sclerosis Impact Scale in
treatment decision-making: Mapping from the MSIS-29 version 2 to the EQ-5D and
the SF-6D. Value Health 2012;15:1084–91.
Thomas S, et al. J Neurol Neurosurg Psychiatry 2013;84:1092–1099. doi:10.1136/jnnp-2012-303816 1099
Multiple sclerosis
 o
n
 3 M
ay 2018 by guest. Protected by copyright.
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2012-303816 on 21 May 2013. Downloaded from 
